A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

Summary

The ARCH study was an open-label, single-center, Phase 1b study of sevasemtem (EDG-5506) to assess the safety and pharmacokinetics (PK) of sevasemten in adults with Becker muscular dystrophy (BMD). Sevasemten is an investigational product intended to protect and improve function of dystrophic muscle fibers.

Timeline

Start

2021-12-28

Primary completion

2024-03-01

Completion

2024-03-01

Drugs

Indications